Crossmark

Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design

Crossref DOI link: https://doi.org/10.1038/s41416-022-01994-1

Published Online: 2022-10-15

Published Print: 2022-12-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Glud, Eske N.

Rasmussen, Martin https://orcid.org/0000-0001-9077-7857
Zhang, Yonghui

Mandrup, Ole A.

Salachan, Paul Vinu

Borre, Michael

Sørensen, Karina Dalsgaard https://orcid.org/0000-0002-4902-5490
Howard, Kenneth A. https://orcid.org/0000-0002-9407-278X
Funding

Funding for this research was provided by:

Novo Nordisk Fonden (NNF17OC0028070, NNF17OC0028070, NNF17OC0028070, NNF17OC0028070)
License Information

Text and Data Mining valid from 2022-10-15

Version of Record valid from 2022-10-15
More Information

Article History

Received: 1 April 2022

Revised: 14 September 2022

Accepted: 16 September 2022

First Online: 15 October 2022

Competing interests

: The authors declare no competing interests.

: This study conforms to the principles of the Helsinki Declaration and was approved by The Central Denmark Region Committees on Health Research Ethics [#2000/0299, #1-10-72-361-18, #1-10-72-367-13] and The National Committee on Health Research Ethics [#1603543/66451] and notified to The Danish Data Protection Agency [#2013–41-2041, #1-16-02-330-13, #1-16-02-23-19, #1-16-02-248-14]. Written consent was obtained from all participants prior to their donation of tissue samples for a research biobank, while the requirement for patient consent to the specific analyses in this study was waived.

: Not applicable.

Document is current

Any future updates will be listed below